MedTrace Logo

Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace

NCT07312474 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-12-31

No results posted yet for this study

Summary

Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace. This infection is responsible for clinical manifestations that are most often mild, including fever, headache, and myalgia, occurring 2 to 3 weeks after a tick bite. However, this infection can be accompanied by potentially serious or even fatal complications, including severe cytopenias, acute respiratory distress syndrome, septic shock, severe neurological disorders, hemorrhagic manifestations, macrophage activation syndrome, and multiple organ failure. Mortality is variable and appears to be higher in American studies, where it is around 4%. Treatment is well-established and relies on doxycycline, which is highly effective. Although a few cases have been described in France, these are mostly isolated cases or short series of cases, whereas Belgium, Poland, and Slovenia have reported numerous cases. Thus, there is a lack of data on French cases, and given that Alsace is in a region with a high prevalence of tick-borne diseases, data is needed to better understand the epidemiology and to better identify suspected cases in order to provide appropriate care.

Conditions

  • Human Anaplasmosis

Sponsors & Collaborators

  • University Hospital, Strasbourg, France

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-02
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07312474 on ClinicalTrials.gov